Protein kinase C inhibitors and uses thereof

Patent metadata

Field	Value
Publication number	US-9913843-B2
Application number	US-201514712748-A
Country	US
Kind code	B2
Filing date	May 14, 2015
Priority date	Dec 4, 2012
Publication date	Mar 13, 2018
Grant date	Mar 13, 2018

Abstract

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

First claim

What is claimed is:

1. A method of inhibiting a protein kinase C (PKC) activity comprising:
contacting a PKC with a compound of formula (I):

wherein
R 11 is selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylthioalkylene, substituted alkylthioalkylene, and SF 5 ;
Y 1 and Y 2 are independently selected from hydrogen and alkyl; and
Ar 1 is selected from aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein the contacting results in inhibition of the PKC activity.

2. A method for inhibiting IL-2 production in T cells, the method comprising contacting T cells with a compound of formula (I):

wherein:
R 11 is selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylthioalkylene, substituted alkylthioalkylene, and SF 5 ;
Y 1 and Y 2 are independently selected from hydrogen and alkyl; and
Ar 1 is selected from aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
or a pharmaceutically acceptable salt or stereoisomer thereof.

3. A method for treating an inflammatory disease or disorder mediated or sustained through a PKC activity, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):

wherein:
R 11 is selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylthioalkylene, substituted alkylthioalkylene, and SF 5 ;
Y 1 and Y 2 are independently selected from hydrogen and alkyl; and
Ar 1 is selected from aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
or a pharmaceutically acceptable salt or stereoisomer thereof.

4. A method for treating an autoimmune disease or disorder mediated or sustained through a PKC activity, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):

wherein:
R 11 is selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylthioalkylene, substituted alkylthioalkylene, and SF 5 ;
Y 1 and Y 2 are independently selected from hydrogen and alkyl; and
Ar 1 is selected from aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
or a pharmaceutically acceptable salt or stereoisomer thereof.

5. A method for treating an ocular disease or disorder involving inflammatory and/or neovascular events mediated or sustained through a PKC activity, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):

wherein:
R 11 is selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylthioalkylene, substituted alkylthioalkylene, and SF 5 ;
Y 1 and Y 2 are independently selected from hydrogen and alkyl; and
Ar 1 is selected from aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
or a pharmaceutically acceptable salt or stereoisomer thereof.

Assignees

• Rigel Pharmaceuticals Inc

Inventors

• Kolluri Rao
• Masuda Esteban
• Tso Kin
• Alvarez Salvador
• Heckrodt Thilo
• Holland Sacha
• Kelley Ryan
• Duncton Matthew
• Singh Rajinder
• Mcmurtrie Darren

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07D455/02

  containing not further condensed quinolizine ring systems · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P27/02

  Ophthalmic agents · CPC title